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A pathogenic link between erectile dysfunction (ED) and metabolic syndrome (MetS) is now well estab-
lished. Nonalcoholic steatohepatitis (NASH), the hepatic hallmark of MetS, is regarded as an active player
in the pathogenesis of MetS-associated cardiovascular disease (CVD). This study was aimed at evaluating
the relationship between MetS-induced NASH and penile dysfunction. We used a non-genomic, high fat
diet (HFD)-induced, rabbit model of MetS, and treated HFD rabbits with testosterone (T), with the selec-
tive farnesoid X receptor (FXR) agonist obeticholic acid (OCA), or with the anti-TNFa mAb infliximab.
Rabbits fed a regular diet were used as controls. Liver histomorphological and gene expression analysis
demonstrated NASH in HFD rabbits. Several genes related to inflammation (including TNFa), activation of
stellate cells, fibrosis, and lipid metabolism parameters were negatively associated to maximal acetylcho-
line (Ach)-induced relaxation in penis. When all these putative liver determinants of penile Ach respon-
siveness were tested as covariates in a multivariate model, only the association between hepatic TNFa
expression and Ach response was confirmed. Accordingly, circulating levels of TNFa were increased
15-fold in HFD rabbits. T and OCA dosing in HFD rabbits both reduced TNFa liver expression and plasma
levels, with a parallel increase of penile eNOS expression and responsiveness to Ach. Also neutralization
of TNFa with infliximab treatment fully normalized HFD-induced hypo-responsiveness to Ach, as well as
responsiveness to vardenafil, a phosphodiesterase type 5 inhibitor. Thus, MetS-induced NASH in HFD rab-nesoid X
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144 L. Vignozzi et al. /Molecular and Cellular Endocrinology 384 (2014) 143–154bits plays an active role in the pathogenesis of ED, likely through TNFa, as indicated by treatments reduc-
ing liver and circulating TNFa levels (T or OCA), or neutralizing TNFa action (infliximab), which signifi-
cantly improve penile responsiveness to Ach in HFD rabbits.
 2014 Elsevier Ireland Ltd. All rights reserved.1. Introduction MetS-associated CVD, most probably through the release of pro-Metabolic syndrome (MetS) is a constellation of medical condi-
tions, including centrally distributed obesity, decreased high-den-
sity lipoprotein cholesterol, elevated triglycerides, elevated blood
pressure, and hyperglycaemia. MetS is recognized as a driver of
the current epidemics of both type 2 diabetes mellitus (T2DM)
and cardiovascular disease (CVD).
MetS, in the male, is also involved in the development of several
non-metabolic diseases, including hypogonadism and erectile dys-
function (ED) (Corona et al., 2011a,b; Traish et al., 2011). A link be-
tween ED and MetS has also been envisaged, because both
conditions are related to high odds of developing cardiovascular
(CV) events (Corona et al., 2011b). In addition, in MetS patients,
an important pathogenic component of ED is the associated hypo-
gonadism (Corona et al., 2011a). Data from a consecutive series of
more than 800 patients with sexual dysfunction indicate that pa-
tients with MetS have a component-dependent higher prevalence
of ED and poorest penile Doppler ultrasound (PDU) parameters
(Corona et al., 2006). However, no difference in terms of ED sever-
ity or PDU parameters was observed when MetS patients were
stratified according to the presence of hypogonadism (Corona
et al., 2006). Hence, the influence of factors other than hypogonad-
ism, impairing hemodynamic mechanisms at both penile and sys-
temic vascular bed levels, has been suggested.
Penile erection is the end result of a complex neurovascular
process in which nerves, endothelium of sinusoids and blood ves-
sels, and smooth muscle cells in the corpora cavernosa (CC) are in-
volved. Indeed, it is well established that the balance between
contractant and relaxant factors modulates the degree of smooth
muscle tone of the CC and determines the functional state of the
penis: flaccidity or erection. The most important and specific path-
way for penile erection is the nonadrenergic/noncholinergic signal-
ing, which through the release of a labile gas, nitric oxide (NO),
leads to erection. Formation of NO is strictly controlled by the
activity of NO synthase (NOS) isoenzymes: endothelial (eNOS)
and neuronal (nNOS). NO activates the soluble guanylyl cyclase
(GC), which increases 3’,5’-cyclic guanosine monophosphate
(cGMP) levels, thus regulating the activity of cGMP-dependent pro-
tein kinase (PKG) and calcium channels that affect the relaxation of
CC smooth muscle. The main hydrolytic enzyme involved in cGMP
breakdown, thus leading to penile flaccidity is the phosphodiester-
ase type 5 (PDE5). In human (Morelli et al., 2004) and rabbit (Mor-
elli et al., 2013) penis expression of PDE5 is at least one-log unit
higher than in other tissues. Impaired NO bioactivity is considered
a major pathogenic mechanism leading to erectile dysfunction
(Vignozzi et al., 2005).
Nonalcoholic fatty liver disease (NAFLD) is considered as the he-
patic hallmark of MetS (Marchesini et al., 2003). The term NAFLD
covers a spectrum of histological findings ranging from simple ste-
atosis to nonalcoholic steatohepatitis (NASH), the most severe
form of NAFLD. Epidemiological studies indicate that NASH pa-
tients are at higher risk for CVD, independently from underlying
cardiometabolic risk factors (Targher et al., 2008). In patients with
NAFLD, the severity of liver injury and inflammation is strongly
associated with increased CV and atherogenic risk (Alkhouri
et al., 2010). This suggests that NAFLD is not merely a marker of
MetS, but may also actively contribute to the pathogenesis ofatherogenic inflammatory factors. This concept could be inferred
to link NAFLD to ED.
The current study addressed this issue by taking advantage of a
non-genomic, high fat diet (HFD)-induced, animal model of MetS
that closely resembles the human MetS phenotype (Filippi et al.,
2009; Vignozzi et al., 2011, 2012a; Maneschi et al., 2012; Maneschi
et al., 2013). This model is characterized by hyperglycaemia, glu-
cose intolerance, hypercholesterolemia, hypertriglyceridemia,
hypertension, increased visceral fat mass, hypogonadotropic hypo-
gonadism, lower urinary tract (LUT) abnormalities (Vignozzi et al.,
2012a), penile alterations (Filippi et al., 2009; Vignozzi et al., 2011)
and NASH (Maneschi et al., 2013). The primary goal of our analysis
was to evaluate the relationship between liver pathology and pe-
nile dysfunction in the course of HFD-induced MetS. The data indi-
cate that MetS-induced NASH plays an active role in the
pathogenesis of ED in HFD rabbits, likely via TNFa. We have re-
cently demonstrated that both testosterone (T; Filippi et al.,
2009; Maneschi et al., 2012) or obeticholic acid (OCA; Vignozzi
et al., 2011; Maneschi et al., 2013) supplementation to HFD rabbits
were able to normalize not only several MetS features, including
visceral adipose tissue dysfunction and insulin resistance, but also
HFD-induced penile alterations, including hypo-responsiveness to
acetylcholine (Ach). Hence, here, we tested whether these treat-
ments can ameliorate also HFD-induced liver alterations, as well
as TNFa circulating level. To test the effect of TNFa neutralization,
a subgroup of HFD animals has been treated with the selective
anti-TNFamAb, infliximab. Interestingly, treatments which reduce
liver and circulating TNFa levels, such as T and the FXR agonist
OCA, or which neutralize TNFa action such as infliximab, signifi-
cantly improve penile responsiveness to acetylcholine (Ach) in this
model.2. Material and methods
2.1. Chemicals
Phenylephrine (Phe) HCl, sodium nitroprusside (SNP), acetyl-
choline (Ach), were purchased from Sigma–Aldrich (St. Louis,
MO, USA). Testosterone (T) supplementation was performed using
T enanthate (250 mg; supplied by Bayer-Schering Pharma, Berlin,
Germany). Obeticholic acid (OCA), a farnesoid-X receptor agonist,
was supplied by Intercept Pharmaceuticals (New York, USA). Var-
denafil, a selective phosphodiesterase type 5 inhibitor (PDE5i)
was supplied by Bayer Schering Pharma AG, Global Drug Discovery
(Wuppertal, Germany). Infliximab, an anti-TNFa chimeric mAb
(Remicade, 100 mg, was from Janssen Biologics B.V. Einsteinweg
101 2333 CB Leiden, The Netherlands).2.2. Animal model
The MetS rabbit model has been obtained by feeding adult male
rabbits a high fat diet (HFD; n = 48) for 12 weeks, as previously de-
scribed (Filippi et al., 2009). A first subgroup of HFD rabbits (n = 28)
was treated with intramuscular injections of testosterone (30 mg/
kg/week), as previously described (Filippi et al., 2009; Vignozzi
et al., 2012a). A second subset of HFD rabbits (n = 18) was treated
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gavage), as previously described (Maneschi et al., 2013). An addi-
tional subset (n = 7) of HFD rabbits was treated with the anti-TNFa
monoclonal antibody, infliximab (5 mg/kg/week, i.v.). Rabbits fed a
regular diet (RD) were taken as controls (n = 79).
2.3. Evaluation of MetS parameters
Blood samples for glucose, total cholesterol, triglycerides, tes-
tosterone and 17b-estradiol were obtained via marginal ear vein
at baseline and at week 12 in all groups, early in the morning after
an overnight fasting. Mean arterial pressure (MAP) and visceral
adipose tissue weight were determined, according to Filippi et al.
(2009). To evaluate the effects of MetS, we designed an algorithm
taking into account the presence, as a dummy variable, of one or
more of the following factors: hyperglycemia, high triglyceride,
high cholesterol, increased blood pressure, and visceral fat accu-
mulation. Cutoffs for each factor were derived by the mean ± two
S.D. of the analyzed parameter, as measured in RD rabbits accord-
ing to (Maneschi et al., 2012). Positivity for three or more factors
identifies MetS.
2.4. Isolation of organs
Rabbits were sacrificed with a lethal dose of pentobarbital and
specimens of several organs [corpora cavernosa (CC), liver, visceral
fat (VAT), hypothalamus, bladder, prostate, testis, skeletal muscle,
and epididymis] were harvested and processed for subsequent
analyses.
2.5. Liver histomorphological analysis
Frozen sections were cut in a cryostat and fixed in 4% parafor-
maldehyde for 20 min at room temperature (RT). Masson’s tri-
chrome staining was performed following the manufacturer’s
instructions (Bio-Optica, Milan, Italy). To evaluate lipid accumula-
tion, the sections were treated for 2–5 min with isopropanol and
stained with Oil Red O for 20 min (Maneschi et al., 2013). A combi-
nation of Periodic Acid-Schiff (PAS) with Giemsa staining was per-
formed following the manufacturer’s instructions (Sigma–Aldrich,
Milan, Italy) to visualize intact glycogen-positive hepatocytes and
nuclei of infiltrating cells, respectively.
2.6. RNA extraction and quantitative RT-PCR
Isolation of total RNA from tissues was performed using TRIzol
reagent (Life Technologies, Paisley, UK) and/or RNeasy Mini Kit
(Qiagen, Hilden, Germany), both according to the manufacturers’
instructions. cDNA synthesis was carried out using the iS-
criptTMcDNA Synthesis Kit purchased from Bio-Rad Laboratories
(Hercules, CA). Quantitative real-time RT-PCR (qRT-PCR) analysis
was performed according to the fluorescent methodology, using
SsoFastTMEvagreen Supermix (Bio-Rad Laboratories). Amplifica-
tion and detection were performed with the MyiQ2 Two-Color
Real-Time PCR Detection System (Bio-Rad Laboratories) using the
following thermal cycler conditions: 40 cycles at 95 C for 30 s
and 60 C for 1 min. Specific PCR primers for rabbit target genes
were designed on rabbit sequences available at NCBI GeneBank
(http://www.ncbi.nlm.nih.gov) or Ensemble Genome (http://
www.ensembl.org), or based on homology to the human sequence,
as reported previously. Primers were purchased from Life Technol-
ogies. A detailed list of the primers used is reported in Table 1. The
expression of PDE5 was quantified with a predeveloped
(Hs00153649_m1; Life Technologies). The expression of the 18S
ribosomal RNA subunit, quantified with a predeveloped assay
(Hs99999901_s1; Life Technologies), resulted the most stable andoptimal for data normalization in comparison with two other
widely used housekeeping genes, GAPDH and b-microglobulin. It
was therefore chosen as the reference gene and used for relative
quantitation of the target genes. Data analysis was based on the
comparative threshold cycle (Ct) method, according to Filippi
et al. (2009).2.7. In vitro contractility studies
Corpora cavernosa (CC) samples were immediately placed and
maintained in cold Krebs solution and in vitro contractility exper-
iments were performed in organ chambers, according to (Filippi
et al., 2009). Briefly, rabbit CC strips were vertically mounted under
1.8 g resting tension in organ chambers containing 10 mL of Krebs
solution at 37 C, gassed with 95% O2 and 5% CO2 at pH 7.4, and al-
lowed to equilibrate for at least 90 min. Changes in isometric ten-
sion were recorded on a chart polygraph (Battaglia Rangoni,
Casalecchio di Reno, Bologna, Italy). The degree of contractile re-
sponse induced by Phe (100 lM) was taken as 100% and the relax-
ant effect induced by different drug (Ach and SNP) concentrations
was referred to this value. Drug cumulative concentrations were
added to the bath, at 3–7 min intervals, in order to obtain concen-
tration-relaxant effect curves. Relaxant response to SNP was mea-
sured after a 30-min pre-treatment with a fixed concentration
(100 nM) of the PDE5i vardenafil.2.8. Quantification of serum TNFa
Serum TNFa content was assayed using a commercially avail-
able rabbit ELISA Kit (Cloud-Clone Corp. Houston, TX, USA) follow-
ing the manufacturer instructions and analyzed by an ELISA plate
reader (Victor3 1420 multilabel counter, Perkin Elmer, MA, USA)
at 450 nm wave length.2.9. Immunohistochemistry for TNFa in corpora cavernosa sections
CC sections were incubated overnight at 4 C with a primary
anti-TNFa antibody (infliximab 1:100 vol/vol, Dako Cytomation,
Copenhagen, Denmark). The sections were rinsed in PBS and incu-
bated with a biotinylated secondary antibody and then with a
streptavidin–biotin-peroxidase complex (Ultravision large volume
detection system anti-polyvalent, Lab Vision, Fremont, CA, USA).
The reaction product was developed with 30,30-diaminobenzidine
tetrahydrochloride as chromogen (Sigma–Aldrich). Control experi-
ments were performed by omitting the primary antibody. The
slides were evaluated and photographed using a Nikon Microp-
hot-FXA microscope. Computer-assisted quantification of TNFa
staining was performed after background subtraction using the
Adobe Photoshop 6.0 Software (Adobe Systems).2.10. Statistical analysis
Results are expressed as means ± S.E.M. for n experiments as
specified. The statistical analysis was performed with a one-way
ANOVA test followed by the Tukey–Kramer post hoc analysis in or-
der to evaluate differences between groups, and p < 0.05 was con-
sidered significant. When data were non-normally distributed,
statistical differences were calculated with Kruskal–Wallis test
and Mann–Whitney U-test was used for comparisons between
groups. Correlations were assessed using Spearman’s method,
and the statistical analysis was performed with the Statistical
Package for the Social Sciences (SPSS, Inc.) for Windows 20.0. Step-
wise multiple linear regressions were applied for the multivariate
analysis, whenever appropriate.
Table 1
List of target genes and the relative primers.
Adiponectin (ADPN) F ACCAGGACAAGAACGTGGAC
R GAAGGAAGCCAGTGGAGATG
Androgenreceptor (AR) F CCGTAACTTGCATGTGGATG
R GCTGTACATCCGGGACTTGT
Bile Salt Export (BSEP) F GAACCTCCAATGGCTGTTGT
R ATTAACAGCGGCACCCATAG
Macrophage marker (CD68) F ACTCCAAGCCCAGATTCAGA
R CCATAGGGGAAGGAGAGGAG
Inducible cyclooxygenase (COX2) F AGTGTGCGATGTGCTCAAAC
R AAAAGCAGCTCTGGGTCAAA
Cholesterol 7 alpha-hydroxylase (CYP7A1) F GCAGGACTTCCCATTCACAT
R CGAAGGTGGAGAGTGTGTCA
Endothelin-1 (ET1) F AGCGAGTAGCAGCTCCAAAG
R CCTGAGCCTGTCAGTGCATA
Endothelin receptor type A (ETA) F AGGGGTGAACAGCACAAAAC
R ATGTTCACTGAGGGCAATCC
Endothelin receptor type B (ETB) F CGTCTGCACCTGCTGAAATA
R AACACGAGGCAGGATACCAC
Fibronectin 1 (FN1) F CCTGCACCAAGAATTGGTTT
R TACGATCGGAGCGTCTCTTT
Farnesoid X receptor (FXR) F CCCCAAGTTCAACCACAGAT
R CCAGATGCTCTGTCTCCACA
Glucose 6-phosphatase (G6Pase) F GGTGCTGGACACCGACTACT
R TTTTTCTTCCCCCGAAAGAT
Th2 lymphocytes transcription factor (GATA3) F AGGCAGGGAGTGTGTGAACT
R CGTCGTGGTCTGACAGTTTG
Guanylate cyclase soluble subunit alpha-3 (GCSa3) F AGTTGTGCAGGCCAAGAAGT
R AGCATGGTGATGACTTGCAG
Guanylate cyclase soluble subunit beta-3 (GCSb3) F CAGGAGCTGGAGATCCTCAC
R TGTCTCAGCTCATTGGCAAC
Interleukin-1b (IL-1b) F CCACAGTGGCAATGAAAATG
R AGAAAGTTCTCAGGCCGTCA
Interleukin-6 (IL-6) F GAACAGAAAGGAGGCACTGG
R CTCCTGAACTTGGCCTGAAG
Interleukin-8 (IL-8) F CTCTCTTGGCAACCTTCCTG
R TTGCACAGTGAGGTCCACTC
Interleukin-10 (IL-10) F AGAACCACAGTCCAGCCATC
R TTTTCACAGGGGAGAAATCG
Interelukin-12 (IL-12) F TGCAGATGAAGCCATTGAAG
R ACGAATCTTGGCATCCTTGT
Monocytechemoattractant protein-1 (MCP-1) F CACCCGGACACCCTCTACTA
R CACATATGCCCAAATTTCCA
Matrix metalloproteinase-2 (MMP2) F CTGCAGGGCAGCGGTCACAG
R TACGGAAGTGCAGGTGCGGC
Matrix metalloproteinase-9 (MMP9) F CCCGACCCGAGCTGACTCCA
R CACACCAGAGGCGCCCATCC
Endothelial nitric oxide synthase (eNOS) F GCACAGTGATGGCAAAGAGA
R TCGAGGGACACCACATCATA
Neuronal nitric oxide synthase (nNOS) F CAACATCGCCGTTCTCTACA
R GGAGTGATACTGCCCGACAT
Phosphoenolpyruvatecarboxykinase (PEPCK) F CTGTGCACATCCCAACTCTC
R CCAGTTGAAGGCCTCGTAAA
Perilipin F AATGTGCATAGTGCCAACCA
R ACGTGACTCGATGTGCTCAG
cGMP-dependent protein kinase (PKG1) F TGGATGACGTTTCCAACAAA
R CACTATGTGGCGCTTCTTGA
Phospholipase A2 (PLPA2) F AAGTACACCCCGCTGCCTGC
R ACGCCTGCAGCCATGACCAC
Peroxisome proliferator-activated receptor a (PPARa) F GGCCTGGCCTTCTAAACATA
R TTCTTGATGACCTGCACGAG
Peroxisome proliferator-activated receptorc (PPARc) F TGGGGATGTCTCATAATGCCA
R TTCCTGTCAAGATCGCCCTCG
Ras homolog gene family, member A (RhoA) F CCCTCCTCATCGTCTTCAGT
R GTCGATGGAGAAGCACATGA
Rho-associated protein kinase 1 (ROCK1) F CGGAAGTGAACTCGGATTGT
R TCCAAATGCACCTCTACCAA
Rho-associated protein kinase 2 (ROCK2) F CTACGGACGGGAATGTGACT
R TGTTAAGAAGGCGCAGATGA
Th17 lymphocytes transcription factor (RORct) F GGGCTTCATACCACCTTGAA
R GTGCTCTGGGCCTATCTCTG
Small heterodimer partner (SHP) F TGCCCAGCATACTCAAGAAG
R CAGGTAGGCGTATTCCTTGG
a-Smooth muscle actin (aSMA) F ACTGGGACGACATGGAAAAG
R TACATGGCTGGGACATTGAA
Sterol regulatory element-binding transcription factor 1 (SREBP1) F CACAGGAGCCACAATGAAGA
R GAACGGTAGCGCTTCTCAAT
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Transforming growth factor-beta (TGFb1) F GCTAATGGTGGACAGCAACA
R GCTGCTCCTGCTGTAACTTG
Tissue inhibitors of metalloproteinases 1 (TIMP1) F CCTTGGGGCATGCCACGGAT
R CGTTCCGCAGTTGTCCAGCGA
Tissue inhibitors of metalloproteinases 2 (TIMP2) F GTCCCTGGACGTGGGAGGCA
R GGATCATGGGGCAGCGCGAG
Toll-like receptor 2 (TLR2) F CCGCGGGTTCCCCAGGTTG
R GGATCTGGAGCGCCCATCGC
Toll-like receptor 4 (TLR4) F GCGGGTGGAGCTGTATCGCC
R CTTGGGTTCAGCCGGGCAGG
Tumor necrosis factor a (TNFa) F GTCTTCCTCTCTCACGCACC
R TGGGCTAGAGGCTTGTCACT
Tumor necrosis factor receptor (TNFR) F CTTGCACAGTGGACCATGAC
R ACACGGTGTCCTGACTCTCC
Vesicle-associated membrane protein 4 (VAMP4) F AAGTTCAAGCGCCACCTAAA
R CCACCTGATTCTGAACATGC
Fig. 1. Treatment with testosterone or OCA ameliorates liver pathology. Liver sections from RD (A–C), HFD (D–F), HFD + T (G–I), and HFD + OCA (J–L) treatments. Panels A, D,
G, and J showMasson’s trichrome staining of liver sections from RD (A), HFD (D), testosterone (T)-treated HFD (G) and OCA-treated HFD rabbits (J), respectively. Panels B, E, H,
and K show lipid accumulation in liver sections, as revealed by Oil Red O staining. Panels C, F, I, and L, show PAS-Giemsa staining of liver sections. Original magnifications 10.
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Table 2
Effect of feeding a high fat diet (HFD) on liver gene expression.
Mean ± SEM p
Inflammation-related genes
TNFa 360.22 ± 51.69 <0.0001
IL-6 282.21 ± 41.37 <0.0001
MCP-1 2122.37 ± 406.21 <0.0001
COX2 876.32 ± 273.83 <0.0001
IL-8 1883.21 ± 382.05 <0.0001
IL-10 985.62 ± 100.65 <0.0001
IL-12 68.11 ± 4.67 0.002
IL-1b 111.74 ± 14.24 0.436
Stellate cell activation-related genes
TGFb 368.60 ± 42.47 <0.0001
RhoA 259.78 ± 30.21 <0.0001
ROCK 1 133.10 ± 12.94 0.143
ROCK 2 117.22 ± 12.26 0.681
aSMA 437.89 ± 72.65 <0.0001
ET1 132.58 ± 11.93 0.029
ETA 355.33 ± 53.89 <0.0001
ETB 197.27 ± 20.08 <0.0001
Fibrosis-related genes
TIMP1 1029.32 ± 166.95 <0.0001
TIMP2 874.11 ± 146.28 <0.0001
MMP2 2057.52 ± 485.26 <0.0001
MMP9 900.54 ± 247.94 <0.0001
FN1 110.71 ± 15.51 0.557
Bile acid metabolism
FXR 132.98 ± 10.79 0.019
SHP 187.21 ± 40.97 0.169
CYP 7A1 301.20 ± 72.97 0.003
BSEP 82.93 ± 7.87 0.120
Immune response-related genes
CD68 1140.20 ± 119.57 <0.0001
GATA3 159.11 ± 28.69 0.272
RORct 81.88 ± 12.75 0.030
TLR2 733.97 ± 134.44 <0.0001
TLR4 356.38 ± 46.28 <0.0001
Steatosis and intermediate metabolism-related genes
PPARc 341.44 ± 32.91 <0.0001
PPARa 69.01 ± 6.96 <0.0001
PLPA2 128.65 ± 17.35 0.413
ADPN 295.51 ± 70.20 0.100
CD 36 98.23 ± 12.00 0.500
Perilipin 260.37 ± 68.64 0.007
PEPCK 54.19 ± 6.03 <0.0001
G6Pase 41.19 ± 5.73 <0.0001
SREBP1 205.52 ± 39.48 0.001
VAMP4 92.40 ± 12.40 0.260
eNOS 126.86 ± 13.89 0.327
AR 126.82 ± 13.98 0.527
Data were obtained by quantitative RT-PCR, expressed as percentage of RD and
statistically compared to RD. Statistical differences between groups were calculated
with Mann–Whitney U-test for comparison of non-normally distributed parame-
ters. p < 0.05 was considered significant.
Table 3
Association between hepatic genes and relaxant responsiveness to Ach.
Ach 3 lM AUC for Ach
r p n r p n
Inflammation-related genes
TNFa 0.618 <0.0001 35 0.636 0.048 10
IL6 0.496 0.002 35 0.723 0.018 10
MCP-1 0.656 <0.0001 37 0.673 0.033 10
IL8 0.645 <0.0001 31 0.821 0.023 7
COX-2 0.662 <0.0001 36   
IL10 0.735 <0.0001 31 0.667 0.050 9
IL1b 0.398 0.027 31 0.881 0.004 8
Immune response-related genes
CD68 0.794 <0.0001 34 0.700 0.036 9
GATA3 0.482 0.005 32   
TLR2 0.618 0.001 25   
TLR4 0.513 0.006 27   
Stellate cell activation-related genes
ETA 0.464 0.007 33   
ETB 0.497 0.003 33   
aSMA 0.514 0.003 32 0.762 0.028 8
RhoA 0.405 0.017 34 0.717 0.030 9
TGFb 0.644 <0.0001 33 0.745 0.021 9
Fibrosis-related genes
TIMP1 0.724 <0.0001 32 0.762 0.028 8
TIMP2 0.485 0.012 26   
MMP2 0.588 0.002 26   
MMP9 0.571 0.003 25   
Intermediate metabolism-related genes
SREBP1 0.475 0.005 34   
PEPCK 0.463 0.007 33   
G6Pase 0.424 0.014 33   
PPARc 0.566 <0.0001 37   
PPARa 0.409 0.012 37
Correlations coefficients (r) and level of significance (p-value) are derived from
univariate analysis. n indicates the number of samples; hyphen-minus () indicates
absence of a significant correlation.
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Animal handling complied with the Institutional Animal Care
and Use Committee of the University of Florence, Florence, Italy,
in accordance to the Italian Ministerial Law # 116/92 and accord-
ing to the criteria outlined in the ‘‘Guide for the Care and Use of
Laboratory Animals’’ prepared by the National Academy of Sci-
ences and published by the National Institutes of Health (NIH pub-
lication 86-23 revised 1985).3. Results
3.1. HFD induces liver pathology typical of NASH
Feeding a high fat diet (HFD) had profound effects on liver his-
tology (Fig. 1). In HFD liver sections, abundant fat accumulationwas evident with a specific staining for lipid accumulation (Oil
Red O). Masson’s trichrome staining showed a marked collagen
deposition, forming fibrotic septa around the centrilobular vein
and within the perilobular space, at sites where fatty degeneration
of hepatocytes (similar to the ballooning of hepatocytes in human
NASH) was evident. Periodic acid-Schiff (PAS)/Giemsa staining
identified marked mononuclear cell infiltrates, visible in the portal
system space.
Feeding rabbits a HFD has also marked effects on gene tran-
scripts in liver homogenates, as determined by qRT-PCR (Table 2).
We found that HFD-induced significant decreases in PPARa, a gene
involved in triglycerides metabolism, in two gluconeogenesis-
associated genes (PEPCK, G6Pase), and in inflammatory genes (IL-
12, RORct). HFD induced a significant increase in the expression
of several genes related to stellate cell activation (ET-1, ETA, ETB,
aSMA, RhoA, TGF-b), fibrosis (TIMP1, TIMP2, MMP2, MMP9), bile
acid metabolism (FXR, Cyp7A1), cholesterol metabolism (SREBP1),
steatosis (PPARc, perilipin, VAMP4) and inflammation (IL-6, MCP-
1, IL-8, COX-2, IL-10, CD68, TLR2, TLR4), including TNFa. Circulat-
ing levels of TNFawere increased by over one-log unit in HFD com-
pared to RD rabbits (RD = 5.45 ± 4.9 pg/mL; HFD = 83.9 ± 23.8 pg/
mL, p < 0.0001).3.2. Relationship between liver pathology and penile dysfunction
We next tested whether the hepatic expression of the afore-
mentioned genes was associated with changes in penile respon-
siveness to several relaxant agents. We analyzed association with
the area under the relaxant dose–response curve (AUC) for: (i)
Ach (or its maximal responsiveness at 3 lM), (ii) the ROCK inhibi-
Table 4
Association between families of hepatic genes and relaxant responsiveness to Ach as
derived by multivariate analysis.
Adj. r p
Inflammation-related genes
TNFa 0.612 0.043
IL6 0.085 0.632
MCP-1 0.184 0.389
COX2 0.152 0.695
IL8 0.136 0.786
IL10 0.224 0.243
IL1b 0.097 0.593
Stellate cell activation-related genes
TGFb 0.571 0.086
RhoA 0.091 0.748
aSMA 0.169 0.572
ETA 0.381 0.073
ETB 0.101 0.691
Fibrosis-related genes
TIMP1 0.446 0.012
TIMP2 0.267 0.210
MMP2 0.654 0.095
MMP9 0.837 0.064
Immune response-related genes
CD68 0.971 <0.0001
GATA3 0.315 0.462
TLR2 0.443 0.410
TLR4 0.054 0.807
Intermediate metabolism-related genes
PEPCK 0.322 0.025
PPARc 0.765 <0.0001
PPARa 0.455 <0.0001
G6Pase 0.023 0.858
SREBP1 0.091 0.359
Correlations coefficients (r) and level of significance (p-value) were derived from
multivariate analysis.
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fixed vardenafil concentration, 100 nM). Spearman correlation
analysis showed no significant associations between all the tested
liver genes and AUC of both Y27632 and SNP (with and without
vardenafil, data not shown). Conversely, several genes related to
inflammation (TNFa, IL-6, IL-1b, MCP-1, IL-8, IL-10, COX-2), im-
mune response (CD68, TLR2, TLR4, GATA3), activation of stellate
cells (RhoA, TGFb, aSMA, ETA, ETB), fibrosis (TIMP1, TIMP2,
MMP2, MMP9), and lipid metabolism (SREBP1, PPARc) were nega-
tively associated to maximal Ach-induced relaxation (Table 3). A
positive association was found among penile responsiveness to
Ach and liver PPARa, PEPCK, and G6Pase mRNA (Table 3). Similar
results were observed when the Ach AUC was evaluated (Table 3).
Considering these correlations, a multivariate analysis was per-
formed to verify the specific relationships of individual gene
expression with Ach-induced maximal response. These genes were
therefore introduced, as covariates, in a series of iterative linear
regression analyses. Adjusted regression coefficients are reported
in Table 4. The genes that retained a positive association with pe-
nile maximal Ach response were PEPCK and PPARa, whereas TNFa,
CD68, TIMP1, PPARc resulted negatively associated.3.3. Treatment with testosterone or OCA ameliorates liver pathology,
reduces TNFa levels and enhances penile responsiveness to Ach
The effects of testosterone or OCA treatments in HFD rabbits on
liver histology and gene expression are reported in Figs. 1 and 2,
respectively. Both treatments ameliorated hepatic fat accumula-
tion and inflammation (Fig. 1), down-regulating TNFa and up-reg-
ulating IL-10 gene expression in liver homogenates (Fig. 2A). Bothtreatments restored HFD-induced eNOS down-regulation and Ach
hypo-responsiveness in the penis (see Table 5).
Increasing numbers of MetS components were progressively
associated with increased hepatic TNFa expression (r = 0.442,
p < 0.001, n = 91; Fig. 2B) and reduced penile maximal responsive-
ness to Ach (r = 0.553, p < 0.001, n = 54; Fig. 2C). Interestingly, he-
patic TNFa expression was negatively associated with penile Ach
responsiveness (r = -0.544, p < 0.001, n = 61, Fig. 2D), which re-
tained statistical significance even after adjusting for confounding
factors, such as VAT weight and T level (Adj. r = 0.566, p < 0.001).
When other putative liver determinants of penile Ach responsive-
ness, as derived from the previous modeling (CD68, TIMP1, PEPCK,
PPARc, PPARa, see Table 3), were introduced as covariates in a
multivariate model, only the association between TNFa and Ach
response was confirmed (Adj. r = 0.364, p = 0.020, n = 45). Con-
versely, no association was observed in the expression of inflam-
mation-related genes (TNFa, IL-6, IL-8, MCP-1) in visceral
adipose tissue and penile responsiveness to Ach (data not shown).
Interestingly, T significantly blunted, whilst OCA reduced with-
out reaching statistical significance, circulating TNFa levels
(Fig. 3A). Both treatments significantly reduced liver TNFa expres-
sion (Fig. 3B). Circulating levels of TNFa in all the experimental
groups were significantly related to TNFa mRNA expression level
within the liver (r = 0.360, p = 0.036, n = 34), but not with expres-
sion in other tissues, as VAT, hypothalamus, skeletal muscle, pros-
tate, seminal vesicles (data not shown). The quantitative
evaluation of TNFa and its receptor (TNFR1) gene expression in a
wide panel of rabbit tissues are shown in Fig. 3C. VAT expresses
the highest density of both TNFa and its receptor. In the penis,
the relative abundance of TNFa and TNFR1 was rather low, and
similar to other urogenital tissues. Neither TNFa (see Fig. 3D) nor
TNFR1 (not shown) mRNA penile expression was affected by
HFD. Similar results were obtained in T- or OCA-treated groups
(Fig. 3D). However, when penile TNFa protein was considered,
we found by computer-assisted quantitative immunohistochemis-
try that the relative levels were increased by at least five fold in
HFD rabbits (Fig. 3G). A scanty staining for TNFa was observed in
penile sections from RD rabbits (Fig. 3E), whereas in the HFD rab-
bits there was a marked positivity in both endothelial and smooth
muscle cells of the vascular bed and cavernous spaces (Fig. 3F).
3.4. Infliximab treatment restores penile responsiveness to relaxant
stimuli
To test the hypothesis that TNFa is involved in HFD-induced Ach
hypo-responsiveness in the penis, we treated HFD rabbits with the
anti-TNFa mAb infliximab (5 mg/kg/week). Infliximab treatment
significantly reduced visceral fat accumulation (HFD = 40.7 ± 1.9 g;
HFD + infliximab = 25.3 ± 5 g, p < 0.02) and estrogen levels
(HFD = 307 ± 38.4 pmol/L; HFD + infliximab = 253.3 ± 114.5 pmol/
L, p < 0.02). Conversely, infliximab treatment did not normalize
HFD-induced low testosterone plasma level (HFD = 1.59 ± 0.31
nmol/L; HFD + infliximab = 0.9 ± 0.21 nmol/L, p = 0.559). No signifi-
cant effects of infliximab dosingwere observed in any of the hepatic
genes examined (data not shown).
In order to determine whether infliximab treatment could ame-
liorate penile function, the in vitro relaxant response of isolated
penile strips to Ach, SNP and SNP + vardenafil was assessed. Inflix-
imab administration fully restored HFD-induced hypo-responsive-
ness to Ach (Fig. 4A). Maximal responsiveness to Ach (3 lM; Fig. 4A
inset) also showed a similar trend, being normalized by infliximab.
We then tested penile responsiveness to increasing concentrations
of SNP, in the presence or absence of a fixed concentration
(100 nM) of vardenafil. In the absence of vardenafil, SNP-induced
relaxant response did not exhibit significant between-group varia-
tions, according to Kruskal–Wallis test (p = 0.097; not shown). On
Fig. 2. Treatment with testosterone or OCA reduces TNFa levels and enhances penile responsiveness to Ach. (A) OCA-(black bars) and testosterone-(T, grey bars) on liver
genes Data were expressed as percentage of variation vs. HFD-induced expression. *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001 vs. HFD. (B–C) Relationship between the
number of MetS components (abscissa) and the liver mRNA expression of TNFa (B) or penile maximal responsiveness to Ach (3 lM; C). (D) Relationship between liver TNFa
mRNA expression (abscissa) and penile responsiveness to Ach (3 lM, ordinate), as derived from univariate Spearman’s regression analysis.
Table 5
Expression of eNOS and responsiveness to acetylcholine in CC from the different experimental groups.
eNOS mRNA AUC Ach Maximal response to Ach (% of Phe-induced contractile response)
RD 100.0 ± 10.6 460.7 ± 32.9 46.8 ± 2.4
HFD 49 ± 6.7 104.4 ± 16.1 9.8 ± 1.6
HFD + T 102.2 ± 18.5 333.9 ± 32.6 41.2 ± 4.9
HFD + OCA 162.0 ± 35.0 278.9 ± 39.9 34.7 ± 4.6
p < 0.05, p < 0.01, p < 0.001 vs. regular diet (RD); p < 0.05, p < 0.01, p < 0.001 vs. high fat diet (HFD). T: testosterone (T); obeticholic acid (OCA); endothelial nitric
oxide synthase (eNOS); AUC: area under the curve; Ach: acetylcholine; Phenylephrine (Phe).
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Fig. 3. Effects of HFD, and testosterone (T) or OCA treatment on TNFa. (A) Serum TNFa levels in the different experimental groups. Data are reported as mean ± SEM(n = 10
rabbits/group). (B) Liver TNFa mRNA expression (expressed as percentage of RD values). (C) TNFa and TNFR1 mRNA in several rabbit tissues (CC: penile corpora cavernosa;
VAT: visceral adipose tissue), reported as mean ± SEM (3 samples/group). (D) TNFamRNA in rabbit penis, reported as the mean SEM (n samples/group; RD n = 46; HFD n = 38;
HFD + T n = 28; HFD + OCA n = 17). Note: TNFa expression was not significantly different at Kruskal–Wallis test (p value is reported within the panel). (E–G)
Immunolocalization of TNFa in endothelium (arrowheads) and smooth muscle cells (asterisks) of rabbit CC (E: RD; F: HFD) (magnification, 10). (G) Computer-assisted
densitometry of TNFa positivity (at least 3 rabbits/group). ***p < 0.01 vs. HFD.
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presence of vardenafil was reduced in HFD rabbits (p < 0.05 vs.
RD), and restored, up to the RD level, in infliximab-treated rabbits.
Infliximab treatment in HFD rabbits increased penile eNOS
mRNA expression (HFD = 49 ± 6.7; HFD + Infliximab = 104.4 ± 30.8;
p < 0.05) up to the level of RD group (p = 0.790 vs. RD). In contrast,
the penile expression of PDE5, PKG1, GCa3, GCb3 and nNOS was
not affected by infliximab treatment (not shown). Among genes
that in penis were down-regulated by infliximab there are TNFa it-
self and TIMP2 (HFD = 84.5 ± 11.4; 104.7 ± 15.6; HFD + inflix-
imab = 26.7 ± 18.3; 48 ± 9.7, respectively, all p < 0.05).
4. Discussion
Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic ste-
atohepatitis (NASH) are the hepatic counterpart of MetS, a condi-
tion often associated with erectile dysfunction (ED). An active
role for liver alterations on ED pathophysiology has been hypothe-
sized (Burra et al., 2010), but never demonstrated. We have previ-
ously reported that feeding rabbits a high fat diet (HFD) induces a
syndromic condition that essentially recapitulates human MetS,
along with associated morbidities, as hypogonadotropic hypogo-
nadism (Filippi et al., 2009; Vignozzi et al., 2011, 2012a; Maneschi
et al., 2012) and fatty liver disease (Maneschi et al., 2013). In the
HFD rabbit model, we now show that MetS-dependent liver alter-
ations are tightly associated with an impaired penile responsive-
ness to acetylcholine (Ach), the main physiological relaxant
stimulus. We also provide evidence that the cytokine TNFa could
bridge the impaired Ach-induced relaxation within penis and liver
alterations. Indeed, in HFD rabbits treatments able to normalize
TNFa liver expression and circulating levels (T and OCA), or to neu-
tralize TNFa action (infliximab), significantly improve penile
responsiveness to Ach.
Fatty liver disease in our experimental model of MetS is charac-
terized by a diffuse lipid accumulation within hepatocytes and byfibrosis and mononuclear infiltration within the central vein
spaces, indicating progression of NAFLD towards overt NASH.
Accordingly, hepatic gene expression analysis indicates that mark-
ers of stellate cell activation (such as aSMA), fibrosis (such as
TIMP1) and inflammation (such as TLR2 and TLR 4, the M1 macro-
phage marker CD68, and several chemokines and cytokines) were
all markedly up-regulated in MetS rabbit livers. Our results are in
keeping with other models of HFD-induced steatohepatitis in rab-
bits (Ogawa et al., 2010). Interestingly, the vast majority of these
hepatic genes were negatively related to penile responsiveness to
Ach. By iterative modeling of families of multivariate analyses,
we found that TNFa expression in the liver is the main determinant
of reduced relaxant response to Ach in penis. Feeding a HFD in-
duced a striking increase not only in TNFa liver expression, but
also in its circulating levels, fifteen-fold higher than in RD.
TNFa is a cytokine crucially involved in NAFLD progression to
NASH (Tilg and Diehl, 2000). Interestingly, an increased plasma le-
vel of TNFa has been linked mechanistically to the endothelial dys-
function underlying many CVDs, including type 2 diabetes,
atherosclerosis, and ED (Carneiro et al., 2010). Indeed, acute in-
tra-arterial infusion of TNFa in humans was demonstrated to sub-
stantially reduce endothelium-dependent relaxation and NO
production (Chia et al., 2003). Vlachopoulos first linked increased
inflammatory biomarkers to ED (Vlachopoulos et al., 2006). Blood
levels of TNFa, along with other pro-inflammatory (IL-6, IL-1b)
and prothrombotic factors, were significantly increased in ED pa-
tients and negatively related to sexual performance (Vlachopoulos
et al., 2006). Similar results were also found in patients with type 2
diabetes mellitus (Araña Rosaínz Mde et al., 2011) and in patients
with obstructive sleep apnea syndrome (Matos et al., 2013). Ani-
mal models involving genetic manipulation of TNFa, have shown
peculiar alterations of erectile function. Transgenic animals over-
expressing TNFa showed erectile dysfunction (Hayward et al.,
2007). Conversely, TNFa knockout mice exhibited enhanced penile
NO-dependent relaxation, as well as increased eNOS expression
Fig. 4. Infliximab treatment restores penile responsiveness to relaxant stimuli. (A) Endothelium-dependent relaxation to increasing concentrations of Ach (1 nM–10 lM)
strips expressed as area under the curve (AUC) or maximal responsiveness to Ach (3 lM, inset) in penis. Data are reported as mean ± SEM (at least five experiments/group).
(B) Relaxation response to increasing concentration of SNP (1 nM–100 lM) in the presence of vardenafil (100 nM). Data are expressed as AUC and reported as mean ± SEM (at
least four experiments/group). Symbols outside the boxes represent outliers.
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duces an endothelial injury in different vascular beds. Interest-
ingly, in endothelial cells TNFa directly suppressed eNOS
expression by inhibiting either its gene promoter activity (Ander-
son and Rahmutula, 2004) or its mRNA stability (Yoshizumi
et al., 1993).
Two distinct receptors mediate the effects of TNFa, TNFR1 and
TNFR2. TNFR1 has a ubiquitous distribution (endothelial and
smooth muscle cells), whereas TNFR2 expression is mostly con-
fined to cell of hematopoietic origin (Ryffel and Mihatsch, 1993).
TNFR1 selectively mediates the majority of the toxic and pro-ath-
erogenic effects of TNFa (Zhang et al., 2010) and is also expressed
by the penis (present study and Carneiro et al., 2010; Long et al.,
2012). However, the relative abundance of TNFa and TNFR1 mRNA
in rabbit penis was rather low and similar to other urogenital tis-
sues. In addition, in penis, feeding a HFD induced a significant in-crease in the distribution of TNFa, but not in its mRNA
expression. These findings suggest that penis is more a target than
a source of TNFa, especially in MetS, in which TNFa plasma levels
are significantly elevated.
Increased visceral adiposity, hypogonadism (Corona et al.,
2011a,b), and NASH (Targher and Day, 2011), are all regarded as
potential determinants in the pathogenesis of MetS-related CVDs.
In MetS, both VAT and liver have been proposed as major source
of TNFa (Traish et al., 2009). In the present study, we found no
association between VAT expression of genes related to inflamma-
tion, including TNFa, and penile responsiveness to Ach. In line with
these results, in a HFD rat model, Li et al. demonstrated that omen-
tectomy (the surgical removal of the whole omentum and its con-
stituent fat) did not decrease serum inflammatory factors (Li et al.,
2013). We should recognize that metabolic complications, as those
described in this MetS model, tend to co-segregate and parallel in
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function end points may represent only concomitant phenomena,
associated with increased systemic TNFa, which can derive from
multiple sites (Traish et al., 2009). However, we found only a sig-
nificant association between circulating levels of TNFa and its he-
patic, but not other tissues (VAT, skeletal muscle and others), gene
expression, indicating that liver is one of the main source of TNFa.
Our previous studies (Filippi et al., 2009; Vignozzi et al., 2011;
Maneschi et al., 2012, 2013) have shown that both T and OCA dos-
ing in HFD rabbits significantly: (i) ameliorate lipid accumulation
and liver inflammation; (ii) decrease TNFa liver expression as well
as circulating TNFa plasma levels; and (iii) normalize impaired Ach
responsiveness and eNOS gene expression levels in the penis.
To further investigate the relative contribution of TNFa in MetS-
related ED, a subgroup of HFD animals were dosed with infliximab
(5 mg/kg weekly),a chimeric mAb used to treat autoimmune dis-
eases, as it binds to TNFa inhibiting its action. Therefore, treatment
with infliximab has been aimed at neutralizing systemic TNF a,
which can derive from a series of tissues, including liver. Infliximab
did not normalize T level, but significantly increased eNOS expres-
sion and normalized Ach responsiveness in penis. Similar effects of
infliximab on penile function have already been observed in a rat
model of HFD/STZ type 2 diabetes (Long et al., 2012). Conversely,
infliximab treatment did not affect either the relaxant response
to SNP (a NO donor, which bypasses endogenous NO formation),
or the expression of genes downstream NO signaling (GCa3,
CGb3, PKG1). It is plausible therefore, as already demonstrated in
other vascular districts (Chia et al., 2003), that TNFa exerts a selec-
tive detrimental effect on endothelium-dependent, but not endo-
thelium-independent, relaxation also in the penis. Another
important observation of the present study is that neutralization
of TNFa by infliximab completely normalized HFD-induced hypo-
responsiveness to the PDE5 inhibitor vardenafil. However, we did
not find any significant effect of infliximab dosing on penile
PDE5 mRNA expression. Hence, the increased responsiveness to
PDE5 inhibitor in infliximab-treated rabbits could be related to
an increased enzymatic activity or NO availability. We recently
demonstrated that variations in PDE5 enzymatic activity, rather
than in its mRNA expression, were responsible for changes in
responsiveness to PDE5 inhibitors (Vignozzi et al., 2012b).
In the HFD-induced MetS model we previously showed that
OCA treatment decreases HFD-induced TNFa gene and protein
up-regulation, as well as lipid accumulation (Maneschi et al.,
2013). Moreover, in a double-blind placebo-controlled study, a 6-
weeks treatment with OCA in patients with type 2 diabetes melli-
tus and NAFLD not only decreased insulin resistance determined
by a 2-stage hyperinsulinemic–euglycemic insulin clamp, a key
determinant in the transition of NAFLD to NASH (Adorini et al.,
2012), but also significantly reduced circulating levels of transam-
inases and c-glutamyl transferase, and reduced liver fibrosis mark-
ers (Mudaliar et al., 2013).
An anti-inflammatory effect of androgens has previously been
reported in preclinical studies of human and rabbit prostate (Vig-
nozzi et al., 2012a, 2013, 2012c). We now extend this evidence
to the liver, suggesting that treating hypogonadism could blunt li-
ver inflammation, thus counteracting the development of MetS-
associated CVD. Androgen deficiency and low circulating T levels
have been demonstrated to be independently associated with
NAFLD/NASH (Kim et al., 2012; Völzke et al., 2010). Recently, sev-
eral reports demonstrated that raising serum T concentrations to
normal levels in hypogonadal patients by treatment with paren-
teral T, along with improving metabolic profile, significantly re-
duces the levels of liver transaminases (Haider et al., 2010;
Traish et al., 2013), and circulating TNFa levels (Kalinchenko
et al., 2010). In a randomized, double-blind, placebo-controlled
study, Hoyos and colleagues showed that 18-week treatment withT significantly reduces liver fat content, as well as decreased arte-
rial stiffness (Hoyos et al., 2012). The impact of androgens upon li-
ver has been studied also by using KO animal models. Interestingly
both hepatic androgen receptor KO mice (Lin et al., 2008) and 5a-
reductase type 1 KO mice (Dowman et al., 2013) developed greater
hepatic steatosis and inflammation than the relative wild type
mice.
We recently demonstrated that T supplementation in HFD-MetS
animals, prevented hypertrophic and dysfunctional expansion of
VAT, restoring lipid droplet handling and insulin sensitivity in adi-
pocytes (Maneschi et al., 2012). We now propose this anti-inflam-
matory effect on the liver as an additional mechanism by which T
could improve metabolic control.
In conclusion, our study demonstrates that increased liver and
plasma TNFa levels, associated with HFD-induced NASH, have a di-
rect, detrimental effect on penile pro-erectile mechanisms. This is
further supported by the observation that the ED induced in this
model of MetS is significantly reduced by treatments, like T and
OCA, able to inhibit TNFa liver expression and plasma levels, or
to neutralize TNFa activity (such as infliximab), which normalize
penile endothelium-dependent relaxation.
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